Navigation Links
Blood-Thinner No Help for Dialysis Treatment
Date:5/13/2008

Plavix didn't improve results for patients who underwent circulatory procedure

TUESDAY, May 13 (HealthDay News) -- A major trial has dashed the hope that the clot-preventing drug Plavix could help in the delicate balancing act needed to establish a blood vessel suitable for dialysis for kidney patients.

Giving Plavix (clopidogrel) did reduce the risk that a blood clot would block the vessel created by combining a vein and an artery, a standard procedure for kidney dialysis. But adding the clot-preventing drug did not increase the number of fistulas, as they are called, that could be used for artificial kidney treatment over the long run, the study authors reported.

The study was done because "early thrombosis [blood clotting] is one of the major causes of fistula failure," said Dr. Laura M. Dember, an associate professor of medicine at Boston University, and lead author of the report.

"What we found was that despite the reduction in thrombosis that was clear enough, there was an equal proportion of fistula failure," Dember said. "What is ultimately important is the usability of the fistula for dialysis."

The researchers published their findings in the May 14 issue of the Journal of the American Medical Association.

About 470,000 Americans have kidney failure and are kept alive by dialysis, in which their blood is run through a machine that filters out impurities. The preferred technique for linking to the artificial kidney is to create a fistula, which has lower rates of thrombosis -- blockage -- and infection than alternatives such as synthetic artery-vein grafts. But many fistulas never mature enough to allow dialysis.

The multi-center trial included 877 people with total or partial kidney failure who underwent surgery to create a fistula. Half were given Plavix for six weeks after the surgery, while the other half were not.

Plavix did reduce the risk of blockage by 37 percent over the six-week period. Among the 866 people who were tested, 12.2 percent of those given Plavix had a blockage, compared to 19.5 percent of those not given the anti-clotting drug.

But Plavix therapy did not reduce the incidence of cases in which the fistula could not be used for dialysis, which was 61.8 percent in those getting the drug and 59.5 percent in those getting a placebo.

The rate of fistula failure was about 50 percent higher than anticipated, Dember said, and that might have an effect on future practice.

"There has been an increased emphasis on trying to create fistulas in as many patients as possible," she said. "So, the criteria have changed. We need to develop better methods for selecting suitable candidates for fistula creation."

The trial also indicated the direction that that research should take, Dember said.

"Our future efforts should be directed at understanding the basic mechanisms of fistula maturation," she said. "If we better understand those mechanisms, we should be able to identify maturity-enhancing interventions."

More information

The basics of kidney dialysis are explained by the U.S. National Library of Medicine.



SOURCES: Laura M. Dember, M.D., associate professor of medicine, Boston University School of Medicine; May 14, 2008, Journal of the American Medical Association


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Mix-Up Behind FDAs Failure to Inspect China Blood-Thinner Plant
2. Blood-Thinner Contaminant Traced to Chinese Plant
3. Clinical trials present better alternatives for dialysis patients
4. Nighttime Home Dialysis a Boon for Kidney Patients
5. Nations Largest Dialysis Patient Organization Recognizes the Achievements of Patients and Leaders in Kidney Care
6. WellBound Teams With Kaiser Permanente to Open New Self-Care Dialysis Center in Sacramento, CA
7. New peritoneal dialysis diagnostic discovered
8. Early intervention dramatically improves outcomes for new dialysis patients
9. Dialysis Corporation of America Announces Third Quarter 2007 Earnings Release Date
10. Renal Solutions, Inc. Announces FDA 510(k) Clearance of New Design of the Allient(R) Sorbent Hemodialysis System for Chronic and Acute Hemodialysis
11. DaVita Emergency Response Efforts Ensure Vital Treatment for More than 700 Kidney Failure Patients in Need of Life-Saving Dialysis Treatments in Areas Affected by Southern California Wildfires
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... ... 04, 2016 , ... All-Star Insurance of Northeast TX has ... of their local community. The agency pledges to select a new beneficiary every ... to bring awareness to important local causes with fundraising and other support, by ...
(Date:5/4/2016)... ... 04, 2016 , ... Dr. Elyson and Dr. Assili, dentist in Northridge ... Wisdom tooth removal, a common dental procedure, is performed for many adolescents and young ... resulting in risks of complications. By providing wisdom tooth removal surgery at their office, ...
(Date:5/4/2016)... NC (PRWEB) , ... May 04, 2016 , ... Francesca ... N.C., changed her life forever with a same-day LASIK procedure at Christenbury ... poor eyesight. Dr. Jonathan Christenbury performed her surgery the same day as her in-office ...
(Date:5/4/2016)... Wylie, TX (PRWEB) , ... May 04, 2016 ... ... new Nightstick all-LED multi-function small and compact tactical (6.7 inch) dual-light flashlights in ... in Las Vegas, model NSP-9842XL (average retail starting at $59.95) uses 2 included ...
(Date:5/4/2016)... Boulder City, Nevada (PRWEB) , ... May 04, 2016 , ... ... against bladder infections. Bladder infections, also called UTIs, have plagued people since the ... medicine, millions of women get bladder infections every year. It's not just a matter ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... May 4, 2016 BiondVax Pharmaceuticals Ltd. ... Ron Babecoff , will be attending the Joseph Gunnar ... . On Thursday, May 5, Dr. Babecoff will ... by Joseph Gunner & Co, taking place at ... that Dr. Babecoff will be using is downloadable from BiondVax,s ...
(Date:5/4/2016)... Jersey , May 4, 2016 ... successful completion of an alternative public offering (APO). This ... owned operating company, Valeritas, Inc. and a private placement ... stock at $5.00 per share. Under the ... May 3, 2016, Valeritas Holdings, Inc. will trade on ...
(Date:5/4/2016)... Research and Markets has ... Keratosis Market and Competitive Landscape Highlights - ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ... Highlights 2016, provides comprehensive insights into Actinic ... Keratosis market valuations and forecast, Actinic Keratosis ...
Breaking Medicine Technology: